218 completed, 96 recruiting, 76 terminated, 65 active not recruiting. 356 Phase 2, 219 Phase 1, 94 Phase 3, 5 Early Phase 1, 5 Not applicable.
Follow nab-paclitaxel: new trials by email Literature Review of nab-paclitaxel trials Research Report on nab-paclitaxel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Withdrawn | Lisata Therapeutics, Inc. | 2030-01-01 | 2025-06-06 | |
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 125 | 2027-02-03 | 2026-08-06 |
| Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma. GnP, FOLFIRINOX - Pancreatic Adenocarcinoma Resectable, Non Metastatic | Phase 2 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 42 | 2027-01-01 | 2026-09-15 |
| Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Carboplatin, Paclitaxel, Nab-paclitaxel - Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Exelixis | 60 | 2026-12-15 | 2026-09-29 |
| Trial of First-line Gemcitabine and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic Cancer Gemcitabine (1000 mg/m2), Nab-paclitaxel, L-glutamine - Pancreatic Cancer | Phase 2 | Not yet recruiting | Jun Gong, MD | 200 | 2026-12-01 | 2026-10-08 |
| MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC PD-1 inhibitor, Carboplatin, Nab-paclitaxel - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-11-01 | 2026-10-21 |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 480 | 2026-10-27 | 2026-10-08 |
| A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer Manganese Chloride, Nab-paclitaxel, Platinum chemotherapy - Ovarian Cancer | Phase 3 | Recruiting | Chinese PLA General Hospital | 120 | 2026-10-12 | 2026-09-16 |
| Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma Rimegepant, Tislelizumab, Nab-paclitaxel - Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC) | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 220 | 2026-10-01 | 2026-09-10 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma Sintilimab, Nab-Paclitaxel, Carboplatin - Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | caohaotian | 300 | 2026-10-01 | 2026-09-18 |
| Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer Relacorilant, Nab-paclitaxel - Recurrent or Metastatic Cervical Cancer | Phase 2 | Not yet recruiting | ARCAGY/ GINECO GROUP | 63 | 2026-10-01 | 2026-08-13 |
| GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC SHR-1701, Apatinib, gemcitabine - Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | West China Hospital | 45 | 2026-09-10 | 2026-09-03 |
| A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) BL-B01D1, PD-1 monoclonal antibody, Nab-paclitaxel - Triple-Negative Breast Cancer (TNBC) | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 436 | 2026-09-02 | 2026-09-30 |
| Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma daraxonrasib, gemcitabine, nab-paclitaxel - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 400 | 2026-08-28 | 2026-10-16 |
| Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma Finotonlimab, Nab-paclitaxel, carboplatin - Head & Neck Cancer | Phase 2 | Not yet recruiting | Tang-Du Hospital | 15 | 2026-08-23 | 2026-08-07 |
| A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel - Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | AbbVie | 168 | 2026-08-17 | 2026-10-13 |
| GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ) GB268, Nab-Paclitaxel, Datopotamab Deruxtecan (Dato-DXd) - Breast Cancer (Locally Advanced or Metastatic) | Phase 1 / Phase 2 | Not yet recruiting | Eddingpharm (Zhuhai) Co., Ltd. | 270 | 2026-08-01 | 2026-07-31 |
| A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC - Solid Tumors | Phase 2 | Recruiting | Bristol-Myers Squibb | 260 | 2026-07-27 | 2026-10-06 |
| Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel - HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 70 | 2026-07-22 | 2026-06-04 |
Showing 20 of 578. Sign in to see all of them.
Pancreatic Neoplasms (160) · Breast Neoplasms (92) · Carcinoma, Non-Small-Cell Lung (80) · Triple Negative Breast Neoplasms (55) · Neoplasm Metastasis (37) · Neoplasms (32) · Lung Neoplasms (22) · Squamous Cell Carcinoma of Head and Neck (18) · Colorectal Neoplasms (16) · Adenocarcinoma (14) · Head and Neck Neoplasms (14) · Melanoma (13) · Parkinson Disease 4, Autosomal Dominant Lewy Body (10) · Carcinoma (9) · Carcinoma, Pancreatic Ductal (9)
ImmunityBio, Inc. (20) · Merck Sharp & Dohme LLC (20) · M.D. Anderson Cancer Center (19) · Hoffmann-La Roche (17) · Celgene (16) · Fudan University (11) · Bristol-Myers Squibb (10) · National Cancer Institute (NCI) (10) · AstraZeneca (8) · Gilead Sciences (8) · Washington University School of Medicine (8) · City of Hope Medical Center (7) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6) · Chinese PLA General Hospital (6) · Eli Lilly and Company (6)
United States (341) · China (154) · Spain (97) · Germany (79) · France (74) · Italy (72) · Australia (67) · South Korea (61) · Canada (60) · Japan (60) · United Kingdom (59) · Taiwan (52) · Belgium (47) · Brazil (42) · Poland (41)
Jared Weiss, MD (5) · Erwei Song, M.D., Ph.D. (3) · Peng Zhang, PhD (3) · Douglas R Adkins, M.D. (2) · Dung Le, MD (2)
PMID 32450725, PMID 34252375, PMID 31401903, PMID 35511917, PMID 37499870, PMID 12049861, PMID 22547591, PMID 24703985, PMID 25579459, PMID 25679067, PMID 25845992, PMID 25961845, PMID 26056183, PMID 26201606, PMID 26254683, PMID 26698868, PMID 26808342, PMID 26869049, PMID 27244882, PMID 27404453, PMID 27701653, PMID 27876675, PMID 28114604, PMID 28315068, PMID 28620884, PMID 28701571, PMID 28869790, PMID 28939558, PMID 29119276, PMID 29158367, PMID 29190925, PMID 29228091, PMID 29232172, PMID 29273007, PMID 29327055, PMID 29346519, PMID 29409469, PMID 29438178, PMID 29441562, PMID 29691300, PMID 29695765, PMID 29861116, PMID 29879283, PMID 30021548, PMID 30053670, PMID 30115734, PMID 30149366, PMID 30220407, PMID 30280635, PMID 30345906
2023 (17), 2016 (12), 2014 (10), 2025 (9), 2017 (8), 2019 (8), 2018 (7), 2015 (6), U10CA180820 (5), P30CA138292 (4), P30CA033572 (3), U10CA180868 (3), U10CA180888 (3), P30CA015083 (2), P30CA015704 (2)